Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
Top Cited Papers
- 7 October 2010
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 116 (14), 2543-2553
- https://doi.org/10.1182/blood-2009-12-261032
Abstract
To identify molecularly defined subgroups in multiple myeloma, gene expression profiling was performed on purified CD138+ plasma cells of 320 newly diagnosed myeloma patients included in the Dutch-Belgian/German HOVON-65/GMMG-HD4 trial. Hierarchical clustering identified 10 subgroups; 6 corresponded to clusters described in the University of Arkansas for Medical Science (UAMS) classification, CD-1 (n = 13, 4.1%), CD-2 (n = 34, 1.6%), MF (n = 32, 1.0%), MS (n = 33, 1.3%), proliferation-associated genes (n = 15, 4.7%), and hyperdiploid (n = 77, 24.1%). Moreover, the UAMS low percentage of bone disease cluster was identified as a subcluster of the MF cluster (n = 15, 4.7%). One subgroup (n = 39, 12.2%) showed a myeloid signature. Three novel subgroups were defined, including a subgroup of 37 patients (11.6%) characterized by high expression of genes involved in the nuclear factor kappa light-chain-enhancer of activated B cells pathway, which include TNFAIP3 and CD40. Another subgroup of 22 patients (6.9%) was characterized by distinct overexpression of cancer testis antigens without overexpression of proliferation genes. The third novel cluster of 9 patients (2.8%) showed up-regulation of protein tyrosine phosphatases PRL-3 and PTPRZ1 as well as SOCS3. To conclude, in addition to 7 clusters described in the UAMS classification, we identified 3 novel subsets of multiple myeloma that may represent unique diagnostic entities.This publication has 39 references indexed in Scilit:
- Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myelomaHaematologica, 2007
- Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocationsLeukemia, 2006
- A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUSBlood, 2005
- Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogeneticsGenes, Chromosomes and Cancer, 2005
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- Multiple MyelomaThe New England Journal of Medicine, 2004
- The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myelomaBlood, 2003
- Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid casesGenes, Chromosomes and Cancer, 2003
- In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expressionBlood, 2003
- Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple MyelomaLeukemia & Lymphoma, 1999